QUALIFY study
Commentary from Dr. Ofer Agid
Considerable advances have been made in recent decades in the management of schizophrenia. A majority of first-episode patients achieve remission of psychotic symptoms within the first year of treatment (Lieberman et al. Arch Gen Psychiatry 1993;50:369-376), and early recurrence rates are low (Zipursky et al. Schizophr Res 2014;152:408-414). Read More
REPORT FROM ECTRIMS – BARCELONA, SPAIN – OCTOBER 7-10, 2015 – The MS-AHSCT Long-Term Outcomes Study Group has compiled data for MS patients undergoing autologous hematopoietic stem cell transplantation (HSCT) during the period 1995-2006 to determine long-term outcomes (Muraro et al. ECTRIMS 2015; abstract 1671). A total of 281 patients from 25 centres were evaluable. The median duration of follow-up was 6.6 years (range 0.2-16 years). Read More
REPORT FROM ECTRIMS – BARCELONA, SPAIN – OCTOBER 7-10, 2015 – There is a need for early intervention with more effective therapies to slow disability progression, according to a series of analyses by the MSBase investigators. Read More
REPORT FROM ECTRIMS – BARCELONA, SPAIN – OCTOBER 7-10, 2015 – The much-anticipated results of the OPERA I and II studies of ocrelizumab in relapsing MS were presented on Friday and indicate that the anti-CD20 monoclonal antibody is highly effective compared to interferon-beta-1a s.c. (Hauser et al. ECTRIMS 2015; abstract 190). Read More